NASDAQ$IRON
Disc Medicine Inc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Reported fourth quarter and full year 2024 financial results and provided a business update.
Disc Medicine reported its Q4 and full year 2024 financial results, highlighting a strong financial position with $490 million in cash, cash equivalents, and marketable securities. The company is targeting an NDA submission for bitopertin in H2 2025 and anticipates initiating a Phase 2 study for DISC-3405 in H1 2025.
- Targeting NDA submission for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 through accelerated approval pathway.
- On track to initiate APOLLO post-marketing confirmatory trial by mid-2025.
- Presented positive update from Phase 1b trial of DISC-0974 in patients with anemia of myelofibrosis (MF) at ASH 2024; initial data from ongoing Phase 2 expected in H2 2025.
- Presented first-in-human SAD/MAD data from Phase 1 trial of DISC-3405 demonstrating proof-of-mechanism; a Phase 2 study in polycythemia vera (PV) expected to initiate in H1 2025.
Headline financials
Revenue & EPS history
Disc Medicine · Revenue · Quarterly
$0
Forward guidance
Disc Medicine anticipates several milestones in the near future, including the NDA submission for bitopertin, initiation of the APOLLO trial, and data readouts for DISC-0974 and DISC-3405.
Tailwinds
- Targeting NDA submission for bitopertin in EPP in H2 2025.
- Initiating APOLLO post-marketing confirmatory trial by mid-2025.
- Initial data from ongoing Phase 2 of DISC-0974 in MF expected in H2 2025.
- Multiple-dose data from ongoing Phase 1b of DISC-0974 in NDD-CKD expected in H2 2025.
- Phase 2 study of DISC-3405 in PV expected to initiate in H1 2025.
Headwinds
- Potential delays in clinical trial timelines.
- Uncertainties in regulatory approval pathways.
- Risks associated with drug development and commercialization.
- Dependence on successful clinical trial outcomes.
- Potential challenges in identifying additional product candidates.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2024
-0.4%
Avg return
Earnings day
-1.7%
Avg return
5 days after
+3.9%
Avg return
30 days after
56%
10 / 18 earnings
Positive
+14.6%
Q3 2021
Best reaction
-12.4%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +1.3% | -3.8% | -10.2% | |
| Q3 2025 | -1.6% | -2.5% | +5.6% | |
| Q2 2025 | -3.4% | +0.1% | +3.0% | |
| Q1 2025 | +2.3% | +3.8% | +14.1% | |
| Q4 2024 | +0.1% | +1.6% | -3.9% | |
| Q3 2024 | -5.3% | -10.7% | -3.5% | |
| Q1 2024 | +3.5% | +8.5% | +33.3% | |
| Q4 2023 | -8.7% | -9.2% | -56.8% | |
| Q3 2023 | +1.7% | +8.1% | +27.8% | |
| Q2 2023 | +0.3% | +1.9% | -1.2% | |
| Q1 2023 | +0.6% | +1.8% | +47.6% | |
| Q4 2022 | -0.6% | +0.7% | +48.4% | |
| Q3 2022 | -0.6% | -4.7% | -2.4% | |
| Q2 2022 | -12.4% | -10.9% | -31.8% | |
| Q1 2022 | +3.6% | +10.1% | +8.6% | |
| Q4 2021 | -3.2% | -7.7% | -11.0% | |
| Q3 2021 | +14.6% | -5.6% | -12.6% | |
| Q2 2021 | +0.2% | -12.8% | +15.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro